Bicara Therapeutics Inc. Common Stock (BCAX) - Stock Analysis
Last updated: May 2, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Cushion ⢠Revenue Absence ⢠Dilution Risk BCAX has a strong cash-rich balance sheet and low debt, but no revenue, persistent losses, and negative cash flow make it a dilution-funded, high-risk name.
Price Behavior
Key Price Behavior Insights: ⢠Fading momentum ⢠Range-bound trade ⢠Reclaim resistance Support Level: $21.3â$21.5 Resistance Level: $23.6â$24.0 BCAX has been mostly range-bound over the last month, with a sharp mid-April pop that faded into lower highs and lower closes, so momentum has weakened and the setup stays defensive unless it reclaims $23.6â$24.0.
Sentiment & News
Key News Insights: ⢠52-week high ⢠Analyst attention ⢠Inducement grant Bicara Therapeutics hit a new 52-week high amid analyst-related attention, while also issuing a routine inducement grant to a new employee.
AI Summary
BCAX has moved from a speculative biotech to a more investable late-stage catalyst story thanks to Phase 3 initiation and a strong cash runway, but the stock remains a binary bet on ficerafusp alfa confirming durable efficacy in 2027 while ongoing burn and dilution keep downside meaningful if the readout disappoints.
Description
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is a bifunctional antibody that combines an EGFR-targeting monoclonal antibody with a domain that binds TGF-β. Founded in 2018 and based in Boston, the company is a subsidiary of Biocon Limited.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 19 | Mar 26 | BCAX | Bicara Therapeutics Inc. Common Stock | BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term. | Closed | +0.7% |